Corcept获得FDA批准用于癌症治疗

2026-03-25 22:55

Shares of Corcept Therapeutics (CORT) surged before a trading halt in the morning hours on Wednesday after the U.S. Food and Drug Administration (FDA) approved its cancer therapy, relacorilant.
Specifically, the FDA has approved the drug under the brand name Lifyorli in combination with chemotherapy nab-paclitaxel as a late-line option for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
In September, the FDA accepted Corcept’s (CORT) New Drug Application (NDA) for relacorilant, assigning July 11 as the target action date.
The NDA was based on data from the company’s Phase 3 ROSELLA and Phase 2 trials in which patients on relacorilant plus nab-paclitaxel witnessed an improvement in progression-free and overall survival compared to those who received nab-paclitaxel monotherapy.

More on Corcept Therapeutics